Century Therapeutics (IPSC) Stock Price, News & Analysis

Company Overview

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Key Stats

• Today's Range: $0.54 to $0.57
• 50-Day Range: $0.49 to $0.66
• 52-Week Range: $0.34 to $2.05
• Volume: 1.03 million shs
• Average Volume: 727,087 shs
• Market Capitalization: $46.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.75
• Consensus Rating: Buy

Century Therapeutics Stock Analysis - MarketRank™

Century Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 427th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Century Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Century Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Century Therapeutics are expected to decrease in the coming year, from ($1.61) to ($1.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Century Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Century Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Century Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.31% of the float of Century Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Century Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Century Therapeutics has recently decreased by 3.60%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Century Therapeutics does not currently pay a dividend.

Dividend Growth

Century Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.31% of the float of Century Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Century Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Century Therapeutics has recently decreased by 3.60%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.13

News Sentiment

Century Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Century Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

2 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,003.00 in company stock.

Percentage Held by Insiders

Only 5.00% of the stock of Century Therapeutics is held by insiders.

Percentage Held by Institutions

50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IPSC Stock Analysis - Frequently Asked Questions

How have IPSC shares performed this year?

Century Therapeutics' stock was trading at $1.01 at the start of the year. Since then, IPSC shares have decreased by 45.1% and is now trading at $0.5540.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) announced its earnings results on Thursday, August, 14th. The company reported ($0.38) EPS for the quarter, meeting analysts' consensus estimates of ($0.38). Century Therapeutics had a negative net margin of 19.10% and a negative trailing twelve-month return on equity of 11.53%.

When did Century Therapeutics IPO?

Century Therapeutics (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Century Therapeutics' major shareholders?

Century Therapeutics' top institutional investors include Jane Street Group LLC (0.52%), Geode Capital Management LLC (0.44%), Marshall Wace LLP (0.16%) and Raymond James Financial Inc. (0.11%). Insiders that own company stock include Brent Pfeiffenberger, Douglas Carr, Gregory Russotti, Adrienne Farid and Luis Borges.
View institutional ownership trends.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Century Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include The RMR Group (RMR), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/22/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPSC
• CIK: 1850119
• Web: www.centurytx.com
• Phone: 267-817-5790
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Century Therapeutics: $3.75
• High Price Target: $6.00
• Low Price Target: $2.00
• Potential Upside/Downside: +576.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$126.57 million
• Net Margins: -19.10%
• Pretax Margin: -18.85%
• Return on Equity: -11.53%
• Return on Assets: -6.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.72
• Quick Ratio: 11.70

Sales & Book Value

• Annual Sales: $6.59 million
• Price / Sales: 7.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.43 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 86,390,000
• Free Float: 82,070,000
• Market Cap: $47.86 million
• Optionable: Optionable
• Beta: 1.78